Organization
Bristol-Myers Squibb Company
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Bristol-Myers Squibb Company
... regimens in development,” Raffat wrote. And that’s a big development for both Bristol-Myers Squibb and AstraZeneca, which are trialing a different approach combining PD-1/PD-L1 inhibitors ...
... included $425 million in milestones, strengthens innovation in a rare blood disease. BMS/IFM TherapeuticsIn a deal that had everything - a young firm, cool technology ...
... by Merck (known as MSD outside the United States and Canada) or Bristol-Myers Squibb, respectively. "TRX518 has demonstrated the ability to reduce immunosuppressive regulatory T ...
... 1. Eli Lilly, Bristol-Myers Squibb, and other drugmakers said they are looking closely at how Spark ...
... Bristol-Myers Squibb’s Opdivo is currently the only immuno-oncology treatment approved to treat kidney ...
... has established funded discovery collaborations with 18 leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck & Co.(USA), Sanofi, ...
... Wave of Immuno-Oncology"report has been added toResearch and Markets'offering. Since Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) first gained Japanese regulatory approval for the treatment of metastatic ...
... Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, ASURAGEN, INC., bioMerieux SA, BRISTOL-MYERS SQUIBB COMPANY, CETICS Healthcare Technologies GmbH, Eli-Lilly and Company, F. Hoffmann-La Roche AG, ...
... the pharmacovigilance market: - Olympus Corporation - HCL Technologies Ltd. - Bristol-Myers Squibb Company - Oracle Corporation (Oracle) - Wipro Limited (Wipro) - Infosys Limited ...
... in the pharmaceutical industry with Squibb, followed by Smith, Kline & French, Bristol-Myers and Ajinomoto. A pioneer in international pharmaceutical licensing and technology transfer, he ...
... entity." Mitch Higashi, VP, U.S. medical health economics and outcomes research at Bristol-Myers Squibb, puts it a bit more delicately. "I worry ICER's way of ...
... Milestone for antibody targeting TIM-3 triggers $5 million payment to Five Prime BMS extends research collaboration term for discovery, development and commercialization for therapeutics in ...
... further expand our gene therapy product pipeline. In addition to AMT-126, our BMS-partnered gene therapy candidate for congestive heart failure, we have a number of ...
... businesses. Prior to joining Dr. Reddy's, Sonig spent nearly 15 years at Bristol-Myers Squibb, where he held several leadership positions in general management, country leadership, ...
... Bristol-Myers Squibb will record a $3 billion charge in the fourth quarter of ...
... Bristol-Myers Squibb Co. said Friday it expects to pay an extra $3 billion in ...
... Johnson & Johnson - Eli Lilly - Abbott LaboratoriesBayer AGNovartis AGPfizer, Inc.Bristol-Myers Squibb (BMS) · This report also discusses the Drivers and Restraints of the ...
... and from new, in the form of Principia SGR and strategic investor Bristol-Myers Squibb. It’s also got its hands on a €40 million ($48 million) ...
... Life Capital, LundbeckFonden Ventures, Omnes Capital, Nestlé Health Science, Principia SGR and Bristol-Myers Squibb. PRESS RELEASE Paris, France and Cambridge, MA, USA – January 4, ...
... today announced a $75 million Series B financing co-led by new investor Bristol-Myers Squibb and existing investor New Enterprise Associates (NEA). Other new and existing ...
... Baxter International Blue Cross Blue Shield of Massachusetts BNY Mellon BP America Bristol-Myers Squibb Caesars Entertainment Capital One CBRE Group Charter Communications Chubb Group of ...
... etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb. Markets Covered: Anti-hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular ...
... archived edition of the presentation will be available later that day. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to ...
... Merck Sharp & Dohme), AstraZeneca, Pfizer and, Takeda. Very few companies like Bristol-Myers Squibb, Novartis, Eisai and Roche are investing on the rare variant, the ...
Want to see the full history on Bristol-Myers Squibb Company? Upgrade to RelSci Pro now!
Start My Free Trial